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Abstract. Definitive diagnosis of malaria requires the demonstration through 
laboratory tests of the presence within the patient of malaria parasites or their 
components. Since malaria parasites can be present even in the absence of 
malaria, and since symptoms of malaria can be manifested even in the absence 
of malaria parasites, malaria diagnosis raises important issues for the adequate 
understanding of disease, etiology and diagnosis. One approach to the 
resolution of these issues adopts a realist view, according to which the needed 
clarifications will be derived from a careful representation of the entities on the 
side of the patient which form the ultimate truthmakers for clinical statements. 
We address a challenge to this realist approach relating to the diagnosis of 
malaria, and show how this challenge can be resolved by appeal to Basic 
Formal Ontology (BFO) and to the Ontology for General Medical Science 
(OGMS) constructed in its terms. 
Keywords: malaria, ontology of general medical science 
1   Introduction 
Malaria is a disease caused by one of four types of Plasmodium usually transmitted to 
humans by the bite of an infected female Anopheles mosquito that previously sucked 
the blood from a person with malaria.1 When a patient is or has been in a country in 
which malaria is prevalent, the disease can be suspected on the basis of both 
symptoms reported by the patient (such as body aches, headache and general malaise) 
and physical findings detected at examination (such as severe chills, high fever, and 
prostration). However, for a definitive diagnosis to be made, laboratory tests must 
demonstrate the presence within the patient of malaria parasites or their components.2 
The parasite life cycle (Figure 1) starts in the human host when Plasmodium 
sporozoites enter the bloodstream after being transmitted via a mosquito bite. From 
there, the sporozoites infect the liver cells and disappear from the bloodstream within 
approximately 30 minutes.   
The sporozoites mature into schizonts, which rupture and release merozoites into 
the blood circulation, where they infect red blood cells. They further undergo asexual 
multiplication: some merozoites mature again into schizonts that lead to more 
merozoites; others differentiate into gametocytes which, when picked up by a second 
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mosquito during a further bite, undergo a series of transformations in this second 
mosquito, leading eventually to the production of new sporozoites that can infect 
another human being. Two types of Plasmodium – P. ovale and P. vivax – can persist 
in the liver of an infected patient and cause relapses by invading the bloodstream 
weeks, or even years, later. 
In some regions people are infected but not made ill by the parasites. This can be 
so even if the patient manifests symptoms of malaria, which are after all quite 
unspecific. According to the Centers for Disease Control and Prevention (CDC) ‘such 
carriers have developed just enough immunity to protect them from malarial illness 
but not from malarial infection. In that situation, finding malaria parasites in an ill 
person does not necessarily mean that the illness is caused by the parasites’2 
(emphasis added). Finally, it is known that patients with sickle cell trait, i.e. people 
who inherited one sickle cell gene and one normal gene, have a reduced likelihood of 
dying from malaria because the replication cycle of the parasite is hampered by this 
condition: infected red blood cells become sickle-shaped and are for this reason 
destroyed in the spleen along with the associated parasite. 
 
 
 
 
Figure 1: Life cycle of Plasmodium parasites2 
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2  Background 
Basic Formal Ontology (BFO)3 is an upper ontology that is intended to provide a 
logically well-structured set of highly general representational units for common use 
across multiple scientific and clinical specialisms. BFO is the foundation for the OBO 
Foundry ontologies4 and for a large variety of other domain ontologies, especially 
within the biomedical sphere (http://www.ifomis.org/bfo/users).  
BFO is designed to serve semantic interoperability of multiple data resources. It is 
built on a realist basis, which means that it is intended to represent exclusively types 
of entities that exist in reality. BFO’s approach thus differs from those approaches 
which rest on information modeling and which are said to be ‘concept based’ or 
‘object oriented’. Because of important distinctions between the realist and concept-
based paradigms, including differences in terminology, communication between the 
groups on either side is not easy. Thus it has been stated that ‘BFO has shortcomings 
for representing medical information at the granular level. Like many philosophy 
based upper ontologies, it suffers from defining accidental properties when they are 
not. This leads to issues in maturation of organisms through development cycles such 
as parasites go through and leads to erroneous classifications’.5  
In response, it must be pointed out that BFO does not use the term ‘property’ since 
this term (like its sister terms ‘class’ and ‘concept’) is subject to too large a variety of 
competing interpretations. This does not however mean that one cannot give a 
definition using the resources of BFO for what is meant by ‘property’ (or by 
‘accidental property’) as these terms are used in specific contexts. It also does not 
mean that BFO is for some reason unable to do justice to scenarios involving complex 
temporal relations between multiple disease-causing processes of the sort 
exemplified, for example, in the case of malaria.  
To test the validity of this latter claim, a challenge was proposed to determine 
whether BFO is capable of representing a scenario under which John, a person on 
rotation living in the Congo, has a blood test drawn that shows sporozoites on the 
smear, in such a way as to be able to answer the following questions: 
 
1. Does John have malaria when there are sporozoites detected on his blood smear?5  
2. How can BFO be used to classify an immature life form as a cause of a disease 
when the causative agent develops internally to the organism and changes its 
stage of life? 
3   Objectives 
Our purpose in addressing this challenge is (a) to document the sorts of 
misunderstandings that advocates of the concept orientation have manifested in their 
approaches to BFO, (b) to highlight the kinds of questions that BFO-users have to ask 
themselves when analyzing real-life problems, and (c) to demonstrate the benefits of 
the realist approach as a robust means of providing upper-level categories in whose 
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terms diverse representations of complex clinical scenarios can be analyzed and 
compared. 
Table 1: Malaria- related definitions from Stedman and CDC 
Malaria (D1 – Stedman): a disease caused by the presence of the sporozoan 
Plasmodium in the erythrocyte phase […] characterized by episodic severe chills and 
high fever, prostration, and occasionally death or immunologically mediated 
sequelae 
Malaria (D2 – CDC): a serious and sometimes fatal disease caused by Plasmodium 
falciparum, P. vivax, P. ovale, or P. malariae. People who get malaria are typically 
very sick with high fevers, shaking chills, and flu-like illness. 
Disease (D3 – Stedman): an interruption, cessation, or disorder of body function, 
system, or organ. 
Disease (D4 – Stedman): a morbid entity characterized usually by at least two of 
these criteria: recognized etiologic agent(s), identifiable group of signs and 
symptoms, or consistent anatomic alterations. 
Disorder (D5 – Stedman): a disturbance of function, structure, or both, resulting 
from a genetic or embryonic failure in development or from exogenous factors such 
as poison, trauma, or disease. 
 
4   Methods 
We based our analysis on definitions (Table 1) from the on-line version of the 
Stedman Medical Dictionary1 and from the web pages on malaria maintained by the 
CDC,2 including http://www.cdc.gov/Malaria. We used the BFO-based Ontology of 
General Medical Science6 (Table 2), formal relationships defined in the Relation 
Ontology7 and additional upper ontology representational units from BFO3. Important 
here are the distinctions between (1) universals and particulars, for instance HUMAN 
BEING versus John, (2) continuants and occurrents, for instance sporozoites versus the 
transformations they undergo, (3) first-order entities on the side of the patient and 
those information entities which are about such first-order entities, for instance John’s 
disease versus some diagnosis made about that disease, (4) qualities and dispositions, 
for instance an organism’s temperature or mass versus its potential to undergo certain 
processes when trigger conditions are satisfied, and (5) diseases and those 
predispositions to disease which belong to a wider group of what are known as ‘risk 
factors’.  
These distinctions imply an analysis according to which the question Does John 
have malaria when there are sporozoites detected on his blood smear? in fact 
amounts to three questions:  
 
(1) What is denoted by the term ‘malaria’?  
(2) Does John have what is called ‘malaria’ under the given circumstances? 
(3) What is required to allow a correct diagnosis of what is called ‘malaria’?  
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5   Results 
There are multiple definitions for ‘malaria’ and ‘disease’ in Table 1 above, and this 
multiplicity is compounded further if other traditional terminologies such as 
SNOMED CT are added into the mix. How, then, can we reconcile the differences 
which arise when clinical data are collected on the basis of such conflicting 
definitions, given that the underlying concepts employed are themselves diverse? 
BFO is designed to provide an answer to this question by providing a common 
basis for analysis that can be accepted by all of the multiple specialist communities 
involved. 
The results of our analysis of the mentioned scenario are presented in Table 3, 
whose columns contain indices for easy reference in the discussion, a unique 
identifier (ID) for the particular entities in reality to which reference is made, a 
description of each such entity in the terms set forth above, and of the relations in 
which it stands to other entities, and also specifications of timeframes during which 
these relationships hold. We assumed in this table that a complete malaria cycle is 
realized in John; deviations from this canonical case are discussed below.  
A number of simplifications are made for reasons of space. Thus we gloss over the 
relationships that obtain between groups and members of those groups, for example 
between individual sporozoites and the groups they form, and also over the distinction 
between an organism such as John and the whole formed by John together with 
associated entities – for example sporozoites – in his interior.   
 
Table 2: Disease-related definitions extracted from the BFO-based Ontology of General 
Medical Science (OGMS) 
Disease (D6): a disposition (i) to undergo pathological processes that (ii) exists in an 
organism because of one or more disorders in that organism. 
Disease Course (D7): the totality of all processes through which a given disease 
instance is realized. 
Disorder (D8): a combination of physical components of or in an organism that is 
clinically abnormal. 
Manifestation of a Disease (D9): a bodily feature of a patient that is (i) a deviation 
from clinical normality that exists in virtue of the realization of a disease and (ii) is 
observable. 
Pathological Process (D10): a bodily process that is a manifestation of a disorder. 
Predisposition to Disease of Type X (D11): a disposition in an organism that 
constitutes an increased risk of the organism’s subsequently developing the disease 
X 
Diagnosis (D12): a conclusion of an interpretive process that has as input a clinical 
picture of a given patient and as output an assertion to the effect that the patient has a 
disease of such and such a type. 
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6   Discussion 
Following OGMS, to assert that something is clinically abnormal is to state (1) that it 
is not part of the life plan for an organism of the relevant type (unlike aging or 
pregnancy), (2) is causally linked to an elevated risk of pain or other feelings of 
illness or of death or dysfunction on the part of the organism, and (3) is such that this 
elevated risk exceeds a certain threshold level.6,8 
Taken together with D8 in Table 2, this implies that the sporozoites found in 
John’s blood smear (#5) provide partial evidence for the presence of a disorder in 
John. First, physical components of this sort satisfy two of the three criteria for 
clinical abnormality: sporozoites do not belong to the life plan of a human being, and 
they are causally linked to an elevated risk of death and dysfunction. However, based 
on the information provided, it is not certain that also the third criterion is satisfied: if 
all sporozoites that were in John’s body prior to the blood tap end up on the smear, 
then there is no longer any risk related to these sporozoites. In that case, there would 
be no entities to which #7 – #11 and #13 in Table 3 would correspond. In a typical 
case, however, sporozoites on a patient’s blood smear indicate that there are or have 
been many more sporozoites in that patient’s body, and thereby indicate that John has 
a disorder. 
The second question is whether John, at that point, has a disease as perceived 
under the OGMS framework, and what entity that disease would be. The determining 
factor, following D6, is whether or not the given sporozoites dispose or predispose to 
pathological processes (D10), i.e. processes that either are changes in the way a 
normal physiological function is realized (e.g. hyperventilation) or have no 
physiological counterpart at all (e.g. inflammation). Clearly, this question, too, can be 
answered positively: the sporozoites penetrate liver cells as a result of which the 
generation of merozoites then starts: these processes have no human physiological 
counterpart and are thus pathological. The disorder in question is thus the bearer of a 
disposition to pathological processes, which means, in OGMS terms, that it is the 
bearer of a disease. 
The third question is whether the disease in question is what is called ‘malaria’. 
Here the answer is less straightforward, and this for a number of reasons. The first is 
that authoritative medical sources are vague about what it is for something to be a 
disease, rather than for a person to have a disease. Often these sources characterize a 
disease as being an illness, sickness, pathological condition, morbid entity, and so 
forth, whereby these terms themselves are either not further defined, or, if they are 
defined, then in a way which leads to circularity or inconsistencies when the provided 
definitions are combined. We could not find a definition for disease to which the CDC 
adheres consistently in its treatment of malaria, and the definitions in Stedman (D3 – 
D5) suffer from analogous shortcomings. 
A second reason is that there are three dispositions in our scenario that may qualify 
as diseases: #4, the disposition to harm John’s liver cells, #9, the disposition to harm 
John’s blood cells, and #11, the disposition in John to develop clinical manifestations 
caused by the presence of mature Plasmodia in his blood cells. The CDC states that 
‘the blood stage parasites are responsible for the clinical manifestations of the 
disease [of malaria]’, these manifestations being, for instance, elevated temperature, 
perspiration, weakness, enlargement of the liver, increased respiratory rate, and so 
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forth. This, together with D2, leads us to conclude that it is #11 that would be 
qualified by the CDC as John’s malaria, though there is some evidence that #13 might 
also be so identified – though this, from the OGMS perspective, would amount to a 
confusion of a disease with the corresponding disease course or series of symptoms. 
D1 and D4 together lead us to conclude that for Stedman, too, either #11 or #13 
would qualify as the disease called ‘malaria’. However, on combining D3 with D5, 
we see that #4, #8, and #9 would also qualify as ‘diseases’ for Stedman, although not 
as ‘malaria’ (because of D1’s explicit reference to the erythrocyte phase). 
Similar analyses can now be provided for the non-canonical scenarios regarding 
the unfolding of the parasite life cycle . For those malarial forms in which parasites 
survive in the liver, the relationships 13, 14, 16, 17 and 19 extend beyond the period 
labeled ‘t5’. For patients with sickle-cell trait or with acquired immunity for malaria 
the analysis is as follows. Such persons may be infected yet not develop clinical 
manifestations related to the infection.  Were this to apply to  John,  this  would  mean 
 
Table 3: Simplified representation of John’s disease history from infection until his first 
malarial attack 
 Ref ID Description Relations Time 
1 #1 John inst-of HUMAN BEING  t1-t7 
2 #2 John’s history inst-of OCCURRENT  
3   has-participant #1 t1-t7 
4 #3 sporozoites in John’s blood inst-of BONA FIDE GROUP  t2-t3 
5   part-of #1 t2-t3 
6   inst-of DISORDER t2-t3 
7 #4 disposition to harm John’s liver cells inst-of DISPOSITION t2-t3 
8   has-bearer #3  t2 
9 #5 portion of John’s blood on a blood 
smear  
part-of #1  t2-t3 
10 #6 sporozoites in John’s blood smear inst-of BONA FIDE GROUP t4-t7 
11   part-of #5 t4-t7 
12   part-of #3  t2-t3 
13 #7 schizonts in John’s liver part-of #1 t5 
14   derives-from #3 t5 
15 #8 process in which #7 participates inst-of PATHOLOGICAL  PROCESS  
16   realization-of #4 t5 
17   has-participant #7 t5 
18 #9 disposition to harm John’s blood 
cells 
inst-of DISPOSITION t5-t7 
19   has-bearer #7  t5 
20 #10 mature Plasmodia in John’s blood part-of #1 t6-t7 
21   derives-from #7 t6 
22   participates-in #2 t6-t7 
23 #11 disposition to cause pathological 
processes characteristic of malaria  
inst-of DISEASE t6-t7 
24   has-bearer #10 t6 
25 #12 clinical manifestations of which 
John is the bearer 
part-of #2  t7 
26 #13 clinical manifestations of John’s 
malaria 
part-of #12  
27   realization-of #11 t7 
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that there would be no counterparts of the entities labeled #12 and  #13 in Table 3 
except in those circumstances where John has another disease whose symptoms 
mimick those of malaria, in which case a counterpart of #12 would exist. Only if John 
should exhibit a total and irreversible immunity against the morbid effects of the 
parasite – he is an absolute immune carrier – would disposition #11 also not be 
present. In case of partial immunity carriers are able to maintain a state of 
homeostasis: pathological processes that are the realization of disposition #11 still 
come into existence, but the body is able to prevent their clinical manifestation. In this 
case, the CDC seems to entertain the proposition that such patients do not have a 
disease. On the OGMS view, in contrast, John would have the disease, though in a 
dormant form. 
7   Conclusion 
Have we been able to successfully respond to the challenge? The answer seems to be: 
yes. 
First, while we follow OGMS in the above in defining ‘disease’ in terms of D6, we 
note that an alternative analysis could be formulated in BFO terms on the basis of a 
definition of ‘disease’ close to that of D7. The latter has the advantage that it is 
favored by many clinicians, but we believe that it faces serious problems in doing 
justice to the wide variations in clinical presentations of many diseases.6  
If the disease of malaria is, as according to D6, a disposition, then we need to 
determine which of the three dispositions #4, #9 or #11 – or perhaps which 
combination of these three dispositions – is most appropriately called ‘malaria’. If, as 
according to D1 and the CDC, #11 is chosen, then #4 and #9 come to be recognized 
as predispositions to malaria, following D11. It then still remains open whether they 
themselves are properly to be classified also as diseases in their own right. 
Whichever decision is taken, it is in each case possible to determine whether or not 
John has malaria under the chosen definition, and if so, when he has the disease. We 
demonstrate this in Table 4 by inspecting three cases: a standard case, a case in which 
a person is a carrier but has developed total immunity, and a case in which this 
immunity is only partial. The question whether, under the distinguished scenarios and 
definitions, a correct diagnosis can be made depends of course on what at any given 
time is known about John.  
 
Table 4: Specification of the time when John has malaria under three possible definitions and 
three case types. 
 
 
Definition for ‘malaria’ based on D6 
exemplified by 
Case type #4 #9 #11 
standard  t2-t3 t5-t7 t6-t7 
absolute immune carrier t2-t3 - t6 
partial immunity t2-t3 t5-t7 t6-t7 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
09
.3
96
0.
1 
: P
os
te
d 
7 
No
v 
20
09
If for instance D6 as exemplified by #9 is chosen as definition for ‘malaria’, and if 
it is not known that John is totally immune, then the blood smear evidence will likely 
lead to an incorrect diagnosis to the effect that John has the disease. The additional 
challenge, i.e. to ‘classify an immature life form as a cause of a disease when the 
causative agent develops internally to the organism and changes its stage of life’, is 
also met. The causal relationship between the immature life form – the sporozoites – 
and the occurrence of clinical manifestations is clearly demonstrated by at least the 
following chain of relationships: 
 
• #1 has-part #3 at t2-t3  (rel 5) 
• #3 derivational-source-of #7 at t2 (rel 14) 
• #7 derivational-source-of #10 at t6 (rel 21) 
• #10 bearer-of #11 at t6  (rel 24) 
• #11 realizes #13 at t7  (rel 27) 
 
It is an open question whether these same challenges can also be met by standard 
information-modeling approaches to the representation of clinical scenarios 
illustrated, for example, by the HL7 RIM.  
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